Because TMCG/DIPY treatment modulates the methylation status and stability of E2F1, we observed that the 4OHT-dependent overexpression of E2F1 positively influences E2F1-mediated cell death in ERα-negative breast cancer cells. Here, E2F1 is linked to breast cancer.